A Set of Phosphatase-Inert “Molecular Rulers” to Probe for Bivalent Mannose 6-Phosphate Ligand-Receptor Interactions by Fei, Xiang et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
David Berkowitz Publications Published Research - Department of Chemistry 
November 2007 
A Set of Phosphatase-Inert “Molecular Rulers” to Probe for 
Bivalent Mannose 6-Phosphate Ligand-Receptor Interactions 
Xiang Fei 
University of Nebraska - Lincoln 
Christopher M. Connelly 
University of Nebraska Medical Center, Omaha, NE 
Richard G. MacDonald 
University of Nebraska Medical Center, Omaha, NE 
David B. Berkowitz 
University of Nebraska - Lincoln, dberkowitz1@unl.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/chemistryberkowitz 
 Part of the Chemistry Commons 
Fei, Xiang; Connelly, Christopher M.; MacDonald, Richard G.; and Berkowitz, David B., "A Set of 
Phosphatase-Inert “Molecular Rulers” to Probe for Bivalent Mannose 6-Phosphate Ligand-Receptor 
Interactions" (2007). David Berkowitz Publications. 4. 
https://digitalcommons.unl.edu/chemistryberkowitz/4 
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in David Berkowitz Publications 
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Accepted Manuscript
A Set of Phosphatase-Inert “Molecular Rulers” to Probe for Bivalent Mannose
6-Phosphate Ligand
-Receptor Interactions
Xiang Fei, Christopher M. Connelly, Richard G. MacDonald, David B.
Berkowitz
PII: S0960-894X(07)01384-4
DOI: 10.1016/j.bmcl.2007.11.094
Reference: BMCL 12282
To appear in: Bioorganic & Medicinal Chemistry Letters
Received Date: 16 October 2007
Revised Date: 19 November 2007
Accepted Date: 19 November 2007
Please cite this article as: X. Fei, C.M. Connelly, R.G. MacDonald, D.B. Berkowitz, A Set of Phosphatase-Inert
“Molecular Rulers” to Probe for Bivalent Mannose 6-Phosphate Ligand-Receptor Interactions, Bioorganic &
Medicinal Chemistry Letters (2007), doi: 10.1016/j.bmcl.2007.11.094
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
 
 
 
 
 
 
 
A Set of Phosphatase-Inert “Molecular Rulers” to Probe for 
Bivalent Mannose 6-Phosphate Ligand-Receptor Interactions 
Xiang Fei,a,§ Christopher M. Connelly,b,§ Richard G. MacDonaldb,* 
and David B. Berkowitza,* 
a
Department of Chemistry, University of Nebraska, Lincoln, NE   68588, USA 
b
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE   68198, USA 
This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT] 
Abstract—A set of bivalent mannose 6-phosphonate “molecular rulers” has been synthesized to examine ligand binding to the 
M6P/IGF2R.  The set is estimated to span a P-P distance range of 16-26 Å (MMFF energy minimization on the hydrated phosphonates).  
Key synthetic transformations include sugar triflate displacement for phosphonate installation and Grubbs I cross-metathesis to achieve 
bivalency.  Relative binding affinities were tested by radioligand displacement assays versus PMP-BSA (pentamannose phosphate-bovine 
serum albumin).  These compounds exhibit slightly higher binding affinities for the receptor (IC50’s  = 3.7-5 μM) than the parent, 
monomeric mannose 6-phosphonate ligand and M6P itself (IC50  = 11.5 ± 2.5 μM).  These results suggest that the use of an ?-configured 
anomeric alkane tether is acceptable, as no significant thermodynamic penalty is apparently paid with this design.  On the other hand, the 
modest gains in binding affinity observed suggest that this ligand set has not yet found true bivalent interaction with the M6P/IGF2R (i.e. 
binding to two distinct M6P-binding pockets).   
 
The mannose 6-phosphate/insulin-like growth factor II 
receptor (M6P/IGF2R) is a type I transmembrane 
glycoprotein that cycles through the Golgi, endosomes, 
and the plasma membrane to carry out its role in the 
transport of lysosomal enzymes to their cellular 
destination.1  The receptor also functions in the binding, 
uptake, and degradation of the mitogen, insulin-like 
growth factor II (IGF-II) and facilitates activation of the 
growth inhibitor, transforming growth factor-?.  The 
ability of the M6P/IGF2R to inhibit cell proliferation, or 
stimulate apoptosis, by these mechanisms has 
implicated the receptor as a tumor suppressor.  The 
IGF-II binding activity of the M6P/IGF2R is mainly 
responsible for its growth suppressor function.  Many 
cancers become growth factor-independent by high-
level expression of IGF-II, which not only binds to the 
M6P/IGF2R, but also to the IGF1R.  The high affinity 
interaction of IGF-II with the IGF1R leads to activation 
of IGF1R signaling pathways that promote cell division 
and survival.2 
 
Figure 1.  M6P ligand binding to the M6P/IGF2R: The alternative “hook 
and ladder” models:  A. One monomeric unit of the M6P/IGF2R 
consisting of the 15 extracellular repeating domains, transmembrane 
domain, and a short cytoplasmic tail.  The M6P/IGF2R is depicted as 
forming a hook-like structure when a ligand bearing two M6P groups 
binds to domains 3 and 9 (lighter shaded ovals).  B.  Two monomeric 
units of the M6P/IGF2R are connected through binding by ligands that 
interact with either domain 3 or 9 of two individual monomeric units to 
form a dimeric ladder-like structure.   
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The extracellular portion of the M6P/IGF2R contains 15 
homologous repeat domains of ~147 amino acid 
residues each.  There are two M6P binding sites located 
in domains 3 and 9, and there is one IGF-II binding site 
in domain 11.3 Binding of high-affinity, M6P-based 
ligands and rapid internalization of extracellular ligands, 
such as IGF-II, are aided by the M6P/IGF2R’s ability to 
dimerize.4,5  York et al. demonstrated that ?-
glucuronidase (hGUS), a homotetrameric lysosomal 
enzyme bearing multiple M6P moieties, stabilized the 
receptor’s dimeric structure by cross-bridging the M6P 
binding sites on two adjacent subunits.5  These data 
support a dimeric model for binding of bivalent M6P-
based ligands by the M6P/IGF2R (Figure 1).  
Importantly, they also observed that hGUS binding 
increased the rate of internalization of the receptor and 
consequently stimulated the degradation of any 
passenger ligands, including IGF-II, by 3- to 4-fold.  
The long-term goal of the present work is to exploit this 
unique property of bivalent M6P ligands as a potential 
strategy for therapeutic intervention in IGF-II-
dependent cancer.   
 
Multivalent interactions between receptors and their 
ligands,6 which are common in biology, involve a multi-
step mechanism in which most of the entropic cost is 
paid by the initial binding event and subsequent 
contacts contribute a favorable enthalpy without further 
sacrifice of rotational and translational entropy.7  The 
resultant high binding affinity in these interactions is 
due to a reduced rate of ligand-receptor dissociation.  
This type of interaction occurs in carbohydrate binding 
to lectins and is particularly important in the binding of 
M6P-bearing oligosaccharides by P-type lectins such as 
the M6P/IGF2R. 
 
 
Figure 2.  Hindsgaul’s model biantennary ligands 
 
Tong et al. demonstrated that there are two M6P 
binding sites per monomeric unit of the M6P/IGF2R.8  
Some native glycoprotein ligands and model 
compounds (e.g. PMP-BSA) display up to 100- to 1000-
fold lower dissociation constants, i.e., higher affinities, 
than ligands bearing a single phosphorylated 
mannoside.  Given that two M6P-binding pockets are 
available per receptor in the monomeric binding model 
and four per receptor in the dimeric model, bi- or 
multivalency may account for this effect.  This could 
result from simultaneous contact with two M6P groups 
on two distinct oligosaccharides.  Alternatively, the 
pioneering work of Varki and Kornfeld suggested that 
such high affinity bivalent binding might also be 
achieved with a single N-linked oligosaccharide 
phosphorylated on the two ultimate mannose residues, 
at the first and third antennae (Figure 2).9  This high 
affinity could arise either from intramolecular contact 
between a single receptor molecule and the two 
phosphate groups on the ligand or by intermolecular 
cooperation between two subunits within a dimeric 
receptor structure, as depicted in Figure 1. 
 
 
Figure 3.  Bock’s tripeptide bis-M6P-bearing ligands 
 
Later work by the Hindsgaul group demonstrated that 
the linkage between the ultimate Man and penultimate 
Man on the phosphorylated branch is important, as an ?-
1,2-glycosidic linkage results in a higher binding 
affinity to the receptor than an ?-1,3-linkage (Figure 
2).10  A series of synthetic multivalent ligands for the 
M6P/IGF2R was prepared by Bock and coworkers, 
using a glycopeptide design.11  The best of these 
compounds bore two mannose disaccharides capped 
with phosphate connected by a core peptide of 3 to 5 
amino acids. A tripeptide version of this compound 
bound the M6P/IGF2R with high affinity, which led to 
the hypothesis of a bivalent M6P-based mechanism.5, 11  
However, upon closer inspection, it appears that the 
exceptional binding affinity of this compound was 
attributable to an anthranoyl group present on the lysine 
?-amino group within the core peptide (Figure 3).  This 
modification increased the affinity by ~200-fold relative 
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to the same compound with an unmodified peptide,11 
presumably through interaction with a hydrophobic 
patch on the receptor proximal to the M6P binding site. 
Considering that the high affinity of this compound did 
not arise from a bivalent M6P-based binding 
mechanism, it is not surprising that York et al. found 
that the compound failed to stabilize the receptor’s 
dimeric structure or to stimulate its rapid 
internalization.5  In summary, there is currently no 
evidence in the literature of a small synthetic compound 
capable of bivalent binding to the M6P/IGF2R by a 
M6P-based mechanism. 
 
 
Scheme 1. Reagents and conditions:  (a) NaH, BnBr, DMF, 0 °C to rt 
(90%); (b) AcOH, Ac2O, H2SO4, 0 °C (82%); (c) 2 TMSOTf, 3-buten-1-
ol, rt (86%); 3 TMSOTf, 4-penten-1-ol, rt (70%); 4 TMSOTf, 5-hexen-1-
ol, rt (63%); 5 TMSOTf, 6-hepten-1-ol, rt (62%); (d) Grubbs I catalyst, 
DCM, 40 °C: 6 (81%); 7 (78%); 8 (69%); 9 (70%); (e) Sodium 
methoxide, methanol, rt (quantitative); (f) 2,6-di-tert-butyl-4-
methylpyridine, Tf2O, DCM, -40 °C; (g) n-BuLi, dibenzyl methyl-
phosphonate, THF, -78 °C (two step yields): 14 (67%); 15 (59%); 16 
(33%); 17 (18%); (h) H2 (balloon pressure),  Pd/C, rt; (i) NH4HCO3 (50 
mM) aqueous solution, rt (two step yields): 18 (66%); 19 (71%); 20 
(68%); 21 (62%). 
 
Thus, the goal of this work is to develop high affinity 
bivalent M6P-based ligands that accelerate disposal of 
IGF-II as a passenger ligand directly in tumors, by 
cross-bridging the M6P/IGF2R thereby enhancing its 
ability to internalize IGF-II.  In our previous work, we 
discovered that the phosphonate is an excellent 
surrogate for phosphate to promote equivalent 
interaction with the M6P binding domains of the 
M6P/IGF2R12,13  The phosphonate has the advantage of 
resistance to hydrolysis with the potential for improved 
pharmacokinetics and efficacy in vivo.  In light of the 
aforementioned studies, we sought to improve affinity 
by building bivalency into such ligands. 
 
We have recently demonstrated proof of principle for a 
Ru-mediated cross-metathesis (CM) route to joining 
two M6P surrogates, of both the malonate and 
phosphonate varieties with a hydrocarbon tether.12 
Herein, we describe the exploitation of this 
methodology to synthesize a series of bis-M6P-
phosphonates, with incrementally increasing tether 
lengths as a sort of “molecular ruler” set to probe for 
such a bivalent interaction with the receptor.  To 
systematically increase tether length in two carbon 
increments, the initial mannosidation reaction was 
performed with a series of terminally unsaturated 
alcohols bearing 4-7 carbons [from 3-buten-1-ol 
through 6-hepten-1-ol (Scheme 1).   
 
Initial studies pointed to the need for a modified 
glycosylation protocol.  The previous work employed 
HCl gas-mediated glycosylation for allyl alcohol itself, 
but this approach gave low yields, in the present work, 
when applied to longer chain alcohols.  Instead, it was 
found that TMSOTf-mediated, Vorbrüggen-type 
glycosylation, using an ?-mannosyl acetate glycosyl 
donor was quite an efficient reaction.  Alkene cross 
metathesis14 and triflate displacement15 then followed as 
the key steps, as before, in constructing these 
compounds.  Following a final alkene 
hydrogenation/global debenzylation step, the free 
tethered sugar phosphonates were obtained.  Pleasingly, 
even with the longest hydrocarbon tether lengths studied 
here, no solubility issues were encountered in preparing 
stock solutions up to 200 mM in a HEPES-saline buffer, 
pH 7.4.  
 
Table 1.  Relative M6P/IGF2R binding affinities 
 
aIC50’s for competitive displacement of radiolabeled PMP-BSA from the 
receptor (n = no. of trials, see SI for details); G6P = glucose 6-phosphate 
bRBA = relative binding affinity, normalized to free M6P; cLength = P-P 
distance, as estimated by molecular mechanics minimization (MMFF). 
For each compound, minimizations were run from five different, chain-
extended starting conformers.  The P-P distances given represent the 
ranges seen for the set of low energy, chain-extended conformers found. 
 
Ligand IC50(n) ?M
a RBAb Mr Lgth
c 
M6P 11.5 ± 2.51 (4) 1.0 340 NA 
G6P >10 (4) NA 282 NA 
18 (6C) 4.76 ± 2.50 (4) 2.63 ± 0.74 666 16.2-
19.5 Å 
19 (8C) 5.03 ± 1.34 (4) 2.39 ± 0.83 694 19.2-
20.9 Å 
20 (10C) 4.44 ± 1.40 (4) 2.65 ± 0.52 722 19.6-
22.7 Å 
21 (12C) 3.70 ± 0.56 (4) 3.02 ± 0.41 750 24.6-
26.0 Å 
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Relative binding affinities to M6P/IGF2R were 
determined by displacement assay using radiolabeled 
PMP-BSA as the tracer in the presence of increasing 
concentrations of each of the synthetic ligands (Table 
1).  All the compounds in this new series showed IC50 
values in the micromolar range with ~2-fold increase in 
RBA compared to M6P alone.  This small increase in 
RBA likely results from the availability of 2 moles of 
M6P per mole of ligand providing a 2-fold increase in 
the effective competitor concentration, as opposed to 
any effect of tether length.   Thus, we conclude that 
these synthetic compounds are binding the M6P/IGF2R 
in a monovalent manner.  Moreover, these results imply 
that the two M6-phosphonate moieties are binding 
essentially independently, and with no apparent 
thermodynamic or conformational penalty paid for the 
linker (possible issues include: position of attachment, 
hydrophobicity, trajectory, etc.)   
 
Dahms and coworkers performed very preliminary 
modeling studies of the whole receptor, based on the 
crystal structure of domains 1-3 using topographical 
information based on the amino acid sequence of each 
domain.16  Using this approach, they estimated the 
intramolecular distance of closest approach between the 
domain 3 and domain 9 M6P binding sites to be ~45 Å.  
In contrast, they estimated the interphosphate distance 
between the M6P caps of a bis-phosphorylated 
oligosaccharide to be ~30 Å.  For comparison, we 
conducted modeling studies of our bis-phosphonate 
ligands to determine if they could span these distances.  
Using Spartan 04, we built the model structures of the 
four compounds and added a cluster of six waters 
around each phosphonate.  In clustering these waters, 
water-proton/phosphonate oxygen distances were set at 
2.5 Å (hydrogen bonding distance).  From energy 
minimization by molecular mechanics methods (Spartan 
04) using the Merck Molecular Force Field (MMFF),17 
one obtains an estimate of the distance between the two 
phosphorus atoms in each synthetic bis-phosphonate 
(Table 1). The longest ligand could have a maximum 
span of ~26 Å (Figure 4).  Based on these estimates, our 
compounds may still be too short to bind in a bivalent 
manner, regardless of which receptor binding model is 
correct.  
 
In addition to the importance of tether length, the 
structure of the tether is critical to development of a 
high-affinity bivalent ligand.  The adventitious binding 
properties of the Bock compound suggest that additional 
binding energy may be achieved by adjusting 
hydrophobicity, charge and/or ?-surface of the tether.11  
Moreover, the success enjoyed by the groups of Bock 
and Hindsgaul, respectively, in attaining 2-3 orders of 
magnitude improved receptor binding over M6P, 
suggests that peptide- or carbohydrate-based linkers 
may be advantageous.  Both such tethers present H-
bond donor/acceptor functionality across the M6P-M6P 
span.  They also confer more rigidity than a simply sp3-
hybridized alkane tether.  Thus, each peptide bond 
really represents a degree of pseudo-unsaturation 
(planarity) with an expected bias toward a transoid 
amide geometry. 
 
 
Figure 4.  One of several low energy chain-extended conformers found 
by an MMFF molecular mechanics minimization on the hydrated 12-
carbon-spaced ligand.  See Table 1 for the P,P-distance range found for 
the set of such conformers. 
 
In conclusion, this study introduces the design and 
successful synthesis of the first array of bis-M6-
phosphonate-presenting “molecular rulers” to measure 
distances between M6P-binding pockets at MPR’s, and 
to distinguish between intramolecular and 
intermolecular modes of bivalent binding.  Although the 
highest M6P/IGF2R binding affinity seen in the ligand 
set is in the micromolar range [IC50 ~ 4 μM], no 
solubility problems or tether penalty issues were 
encountered. Moreover, the replacement of the M6P 
ester with a hydrolytically stable phosphonate surrogate 
persists as an effective design, across the entire set, and 
reinforces the notion that phosphatase resistance can be 
incorporated into such small molecule probes.  
Completion of these studies will require that we find a 
high-affinity ligand that stabilizes the dimeric structure 
of the receptor and thereby promotes rapid 
internalization of IGF-II in a cellular model.  
Ultimately, a new compound that exhibits all these 
properties would potentially be testable in an animal 
model for inhibition for IGF-II-driven tumor growth. 
 
In closing, we note that the combination of cross-
metathesis to build the bivalent sugar scaffold, and bis-
triflate displacement to introduce the phosphate-
surrogate late in the synthesis, is a powerful approach.  
This strategy is likely amenable to the introduction of 
other phosphate-mimicking functionality in the 
endgame, and more generally, is likely extendible to the 
study of other multivalent ligand-protein interactions. 
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The synthesis of bivalent, M6P-based phosphonates and their evaluation for M6P-IGF2R binding is reported.
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